TITLE:
Waning of Anti-Spike IgG Antibody Titer after COVID-19 Vaccination: Myth or Reality?
AUTHORS:
Laurent Dupoirieux
KEYWORDS:
SARS-CoV-2, COVID-19 Vaccines, Anti-Spike IgG Antibodies
JOURNAL NAME:
Journal of Biosciences and Medicines,
Vol.11 No.8,
August
8,
2023
ABSTRACT: This observational prospective study was conducted on 25 patients who had received a full 3-dose COVID-19 vaccination scheme with a follow-up ranging from 12 to 19 months after the last injection. The aim of the study was focused on a single biological indicator the anti-spike IgG antibody titer. The age of the patients ranged from 51 to 85 years old. 15 out 25 patients (60%) presented a comorbidity. Our data showed a persistent positive anti-spike IgG antibodies titer ranging from 105 to 5680 BAU/mL (mean: 2661 BAU/mL) in all patients. In view of these results, systematic administration of a SARS-CoV-2 vaccine booster is questionable and should be individually tailored according to the patient medical condition and the anti-spike IgG antibody level.